Tricida, Inc.
TCDA
$0.00
Change (1 day)
$13.85
Year High
$0.04
Year Low
Categories
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Tricida, Inc. (TCDA) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2021 | 120.43 M | 168.29 M | 168.51 M | 145.54 M | |
| 2020 | -122,732,000 | 242.81 M | 315.13 M | 314.02 M | |
| 2019 | 40.87 M | 107.94 M | 371.83 M | 312.74 M | |
| 2018 | 204.81 M | 53.32 M | 247.85 M | 244.35 M | |
| 2017 | -9,858,000 | 11.44 M | 70.66 M | 69.51 M |